Abstracts tagged "radiography"

Abstract Number: 561 • 2018 ACR/ARHP Annual Meeting
U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Maxime MA Verhoeven¹, Maria JH de Hair², Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Xavier M Teitsma², Jacob van Laar², Floris PJG Lafeber², Johannes W. J. Bijlsma⁵ and Johannes W. G. Jacobs⁶, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Roche Nederland BV, Woerden, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The U-Act-Early trial was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission, with step-up…
Abstract Number: 1443 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Criteria for the Diagnosis of Erosive Rheumatoid Arthritis Disease Using Osteoarthritic Patients As Controls Compared to Validated Radiographic Criteria
Camille Roux¹, Frédérique Gandjbakhch², Audrey Pierreisnard³, Marion Couderc⁴, Cédric Lukas⁵, Racha Masri¹, Jean-Philippe Sommier¹, Isabelle Clerc-Urmès⁶, Cedric Baumann⁷, Isabelle Chary-Valckenaere⁸ and Damien Loeuille⁹, ¹Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ²UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ³APHP, Paris, France, ⁴Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Rheumatology, Lapeyronie Hospital and EA2415 Montpellier University, Montpellier, France, ⁶CHRU Nancy, Nancy, France, ⁷CHRU Nancy, Vandoeuvre les Nancy, France, ⁸Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France, ⁹Rheumatology, University Hospital of Nancy, NANCY, France
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease (1,2) responsible for structural damage. Radiography (RX) is considered as the gold standard…
Abstract Number: 1444 • 2018 ACR/ARHP Annual Meeting
Optimization of Ultrasonographic Examination for the Diagnosis of Erosive Rheumatoid Arthritis Versus Erosive Osteoarthritis with Radiography Considered As Gold Standard
Camille Roux¹, Frédérique Gandjbakhch², Audrey Pierreisnard³, Marion Couderc⁴, Cédric Lukas⁵, Racha Masri¹, Jean-Philippe Sommier¹, Isabelle Clerc-Urmès⁶, Cedric Baumann⁷, Isabelle Chary-Valckenaere⁸ and Damien Loeuille¹, ¹Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ²UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ³APHP, Paris, France, ⁴Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁶CHRU Nancy, Nancy, France, ⁷CHRU Nancy, Vandoeuvre les Nancy, France, ⁸Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease (1,2) responsible for structural damage. Radiography (RX) is considered as the gold standard…
Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Peter M. ten Klooster^1,2, Laura M.M. Steunebrink³, Letty Versteeg⁴, Inmaculada de la Torre⁵, Francesco de Leonardis⁶, Walid Fakhouri⁶, Liliana Zaremba-Pechmann⁶ and Mart van de Laar^1,3, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ³Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
Abstract Number: 533 • 2017 ACR/ARHP Annual Meeting
Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
Désirée van der Heijde¹, Jürgen Wollenhaupt², Stanley B Cohen³, Sander Strengholt⁴, Ketti Terry⁵, Ryan DeMasi⁶, Kenneth Kwok⁷, Irina Lazariciu⁸ and Lisy Wang⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸QuintilesIMS, Saint-Laurent, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The long-term safety and clinical efficacy of tofacitinib 5 and 10 mg…
Abstract Number: 1366 • 2017 ACR/ARHP Annual Meeting
Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients
Nevin Hammam^1,2, Shaimaa Salah³, Anthony Marotta⁴ and Emad F. Kholef⁵, ¹Rheumatology and Rehabilitation Department, University of Assiut, Assiut, Egypt, ²University of Alberta, Edmonton, AB, Canada, ³Rheumatology, Rehabilitation and Physical Medicine department, Faculty of Medicine, Assiut, Assiut, Egypt, ⁴Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁵Clinical Pathology Department, Aswan University Hospital, Aswan, Egypt
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in severe joint damage and physical disability, therefore, the discovery of new marker(s) for…
Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Regina Kurrasch⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Keio University School of Medicine, Tokyo, Japan, ³University of Toronto, Newmarket, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…
Abstract Number: 2448 • 2017 ACR/ARHP Annual Meeting
Increased Cumulative Exposure to Tumor Necrosis Factor Inhibitors Reduces Radiographic Progression in US Veterans with Rheumatoid Arthritis in Real World Clinical Practice
Grant Cannon¹, Alan R. Erickson², Chia-Chen Teng, MS¹, Tina Huynh¹, Sally W. Wade³, Bradley S. Stolshek⁴, David Collier⁵, Alex Mutebi⁶ and Brian C. Sauer, PhD¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Wade Outcomes Research and Consulting, Salt Lake City, UT, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Global Health Economics, Amgen Inc., Thousand Oaks, CA
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) have been proven to reduce progression of structural joint damage in rheumatoid arthritis (RA) in randomized clinical…
Abstract Number: 2458 • 2017 ACR/ARHP Annual Meeting
Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy
Xavier M Teitsma¹, Johannes WG Jacobs¹, Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Floris PJ Lafeber⁵ and Johannes W.J. Bijlsma², ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: In early rheumatoid arthritis (RA), starting therapy as soon as possible is important to reduce disease activity and preserve the joints. With application of…
Abstract Number: 2806 • 2017 ACR/ARHP Annual Meeting
Integrated Longitudinal Analysis Increases Precision and Reduces Bias: A Comparative 5-Year Analysis in the DESIR Cohort
Alexandre Sepriano¹, Sofia Ramiro², Désirée van der Heijde¹, Maxime Dougados³, Pascal Claudepierre⁴, Antoine Feydy⁵, M. Reijnierse⁶, Damien Loeuille⁷ and Robert B.M. Landewé⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Paris-Descartes University,, Paris, France, ⁴Hôpital Henri Mondor, Créteil, France, ⁵Univ. Paris Descartes, PRES Sorbonne Paris Cité, Service de radiologie B, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, Paris, France, ⁶Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ⁸University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands
Background/Purpose: Evaluation of imaging is important in spondyloarthritis (SpA) research, but loss to follow up often jeopardizes interpretation of the evaluation. The Interpretation may further…
Abstract Number: 2534 • 2016 ACR/ARHP Annual Meeting
Radiographic Remission in Patients with Seropositive RA at Ten Years after Diagnosis, Treated in a Real Life Setting
Tuulikki Sokka¹, Juha Asikainen¹, Tuomas Rannio^1,2 and Pekka Hannonen¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Radiographs of hands and feet represent an objective outcome measure of rheumatoid arthritis (RA). Joint damage is a result of cumulative disease activity over…
Abstract Number: 2621 • 2016 ACR/ARHP Annual Meeting
Incremental Benefit of Radiographic Inhibition on Long-Term Outcomes in Patients with Rheumatoid Arthritis
Edward C. Keystone¹, Keith A. Betts², Casey A. Schlacher³, Yan Song², Arijit Ganguli³ and Jenny Griffith³, ¹University of Toronto, Toronto, ON, Canada, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: For the treatment of rheumatoid arthritis (RA) a therapeutic window of opportunity exists– patients treated early have favorable outcomes compared with patients treated after…
Abstract Number: 2650 • 2016 ACR/ARHP Annual Meeting
Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Xiaoming Li⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³University of Toronto and Southlake Regional Health Centre, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: In the SIRROUND-D study, sirukumab, a human anti–IL-6 cytokine monoclonal antibody, significantly reduced radiographic progression after 52 wks of treatment vs placebo in patients…
Abstract Number: 592 • 2016 ACR/ARHP Annual Meeting
Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Alan R. Erickson², Chia-Chen Teng³, Tina Huynh³, Sharon Austin⁴, Bradley S. Stolshek⁵, Alex Mutebi⁶, David Collier⁵, Sally W. Wade⁷ and Brian Sauer³, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴VAMC, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Amgen, Thousand Oaks, CA, ⁶Global Health Economics, Amgen, Thousand Oaks, CA, ⁷Wade Outcomes Research and Consulting, Salt Lake City, UT
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective therapy for rheumatoid arthritis (RA) and have been shown to reduce progression of joint structural damage…
Abstract Number: 610 • 2016 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials
Erin Murray¹, Yekaterina Butylkova¹, Alexandra Ellis¹, Martha Skup², Jasmina Kalabic³ and Vishvas Garg⁴, ¹Doctor Evidence, Santa Monica, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc, North Chicago, IL
Background/Purpose: Previously, several studies have meta-analyzed clinical, functional or structural efficacy of biologics in treating rheumatoid arthritis (RA) patients. However, the comparative efficacy of biologics…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].